AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8033573 — intervention group
Group type: COMPARATOR
Intervention: No acyclovir (Control)
Number of subjects: 22
Study 2575375 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing Retraining with Cognitive Restructuring (BRCR)
Number of subjects: 0
Study 2575375 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded self‐exposure in vivo (EXP)
Number of subjects: 0
Study 2575375 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BRCR and EXP
Number of subjects: 0
Study 2575375 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (BRCR, EXP, Combination)
Number of subjects: 0
Study 1097600 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoamphetamine
Number of subjects: 22
Study 1097600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 22
Study 31126345 — intervention group
Group type: EXPERIMENTAL
Intervention: Families Improving Together (FIT) for Weight Loss intervention
Number of subjects: 82
Study 23246443 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led structured PA session
Number of subjects: 200
Study 23246443 — intervention group
Group type: COMPARATOR
Intervention: No structured PA session
Number of subjects: 200
Study 21716975 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated glass fiber posts
Number of subjects: 144
Study 21716975 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom‐made glass fiber posts
Number of subjects: 144
Study 21716975 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite cores without posts
Number of subjects: 144
Study 21716975 — intervention group
Group type: COMPARATOR
Intervention: Gold alloy‐based posts and cores
Number of subjects: 144
Study 18295060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 0
Study 18295060 — intervention group
Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 0
Study 16483549 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone and/or acamprosate
Number of subjects: 160
Study 16483549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 12879276 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 5-ml intramuscular injection of 250 mg fulvestrant
Number of subjects: 100
Study 12879276 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 2.5-ml intramuscular injections with a total of 250 mg fulvestrant
Number of subjects: 100
Study 10651750 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated acromegalic patients
Number of subjects: 19
Study 10651750 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated acromegalic patients (with slow-release octreotide)
Number of subjects: 19
Study 10651750 — intervention group
Group type: COMPARATOR
Intervention: GH-deficient patients (without GH replacement)
Number of subjects: 19
Study 10651750 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-deficient patients (during GH replacement)
Number of subjects: 19
Study 10651750 — intervention group
Group type: EXPERIMENTAL
Intervention: Acromegalic patients and GH-deficient patients (both treated and untreated)
Number of subjects: 19
Study 9350368 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal extubation
Number of subjects: 80
Study 9350368 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA removal
Number of subjects: 80
Study 9350368 — intervention group
Group type: COMPARATOR
Intervention: Comparison of extubation vs LMA removal
Number of subjects: 80
Study 1610026 — intervention group
Group type: EXPERIMENTAL
Intervention: Slo-bid 800 mg once-a-day in the morning for 2 weeks
Number of subjects: 12
Study 1610026 — intervention group
Group type: EXPERIMENTAL
Intervention: Slo-bid 800 mg once-a-day in the evening for 2 weeks
Number of subjects: 12
Study 1610026 — intervention group
Group type: COMPARATOR
Intervention: Theo-Dur
Number of subjects: 12
Study 1610026 — intervention group
Group type: COMPARATOR
Intervention: Theo-24
Number of subjects: 12
Study 4037866 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation nurse assistance during early weeks after parturition (both in hospital and at home)
Number of subjects: 0
Study 4037866 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lactation nurse assistance)
Number of subjects: 0
Study 30904402 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-threat message condition
Number of subjects: 117
Study 30904402 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate threat message condition
Number of subjects: 117
Study 30904402 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threat message condition
Number of subjects: 117
Study 30904402 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 117
Study 27870481 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04937319 (split-dose, 150+100 mg)
Number of subjects: 0
Study 27870481 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04937319 (once daily, 300 mg)
Number of subjects: 0
Study 27870481 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (100 mg once daily)
Number of subjects: 0
Study 24318457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel ligatures placed 3, 5, 10 cm from the tumor proximally and distally before dissection
Number of subjects: 20
Study 24318457 — intervention group
Group type: COMPARATOR
Intervention: No ligatures placed until immediately before specimen removal
Number of subjects: 20
Study 23488264 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0
Study 20878044 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice/week training (group 1)
Number of subjects: 40
Study 20878044 — intervention group
Group type: EXPERIMENTAL
Intervention: Once/week training (group 2)
Number of subjects: 40
Study 20878044 — intervention group
Group type: EXPERIMENTAL
Intervention: Once/2 weeks training (group 3)
Number of subjects: 40
Study 20878044 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 40
Study 18061012 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Information Systems (CIS) implementation
Number of subjects: 0
Study 15284729 — intervention group
Group type: COMPARATOR
Intervention: Normal pregnancy (n=61)
Number of subjects: 122
Study 15284729 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset preeclampsia (<=34 weeks)
Number of subjects: 122
Study 15284729 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe preeclampsia
Number of subjects: 122
Study 15284729 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 122
Study 11338723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream, 0.05%
Number of subjects: 125
Study 11338723 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone-17-butyrate cream, 0.1%
Number of subjects: 125
Study 9251612 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG-CSF (75 micrograms/day, subcutaneously)
Number of subjects: 29
Study 9251612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhG-CSF)
Number of subjects: 29
Study 7948154 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% podophyllotoxin solution
Number of subjects: 0
Study 7948154 — intervention group
Group type: COMPARATOR
Intervention: 25% podophyllin resin
Number of subjects: 0
Study 3215869 — intervention group
Group type: COMPARATOR
Intervention: Ambient CO at 0 ppm
Number of subjects: 23
Study 3215869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient CO at 50 ppm
Number of subjects: 23
Study 3215869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient CO at 100 ppm
Number of subjects: 23
Study 3215869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient CO at 150 ppm
Number of subjects: 23
Study 3215869 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude at 55 m
Number of subjects: 23
Study 3215869 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude at 3,048 m
Number of subjects: 23
Study 3215869 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 23
Study 3215869 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal work loads
Number of subjects: 23
Study 3215869 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude and CO hypoxias
Number of subjects: 23
Study 3215869 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing altitude
Number of subjects: 23
Study 29878044 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal FADS1 variant rs174546
Number of subjects: 898
Study 29878044 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring and maternal FADS3 variants
Number of subjects: 898
Study 29878044 — intervention group
Group type: EXPERIMENTAL
Intervention: rs174450 minor allele homozygotes
Number of subjects: 898
Study 27212198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab-induced skin rash (grade 2 to 4)
Number of subjects: 602
Study 27212198 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab-induced skin rash (grade 2 to 4) in p16-negative patients
Number of subjects: 602
Study 27212198 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute in-field radiation dermatitis (grade 2 to 4)
Number of subjects: 602
Study 27212198 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab-induced skin rash (grade 0 to 1)
Number of subjects: 602
Study 26251182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Heart Failure (AHF)
Number of subjects: 10730
Study 26251182 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub‐Acute Heart Failure (sub‐AHF)
Number of subjects: 10730
Study 26251182 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Heart Failure (Cr‐HF)
Number of subjects: 10730
Study 22685164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS) - 18-24 g protein and 500 kcal per day
Number of subjects: 126
Study 22685164 — intervention group
Group type: COMPARATOR
Intervention: Hospital diet only (Control)
Number of subjects: 126
Study 22685164 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS)
Number of subjects: 126
Study 21913864 — intervention group
Group type: COMPARATOR
Intervention: 3 × 15 minutes (n=15)
Number of subjects: 30
Study 21913864 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 45 minutes (n=15)
Number of subjects: 30
Study 18254433 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring group (tutoring conversational skills to ESL students for 1 hour twice per week for 12 weeks)
Number of subjects: 0
Study 18254433 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 0
Study 18254433 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentoring group
Number of subjects: 0
Study 16303153 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 hours of sleep)
Number of subjects: 17
Study 16303153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprived group (2 hours of sleep)
Number of subjects: 17
Study 12684745 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) with immune-enhancing formula
Number of subjects: 39
Study 12684745 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (PN)
Number of subjects: 39
Study 12684745 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN)
Number of subjects: 39
Study 10856142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 20 mg
Number of subjects: 565
Study 10856142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 565
Study 10856142 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 565
Study 10856142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565
Study 9663841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual or triple combination therapies including one proton pump inhibitor (30 mg/day lansoprazole or 20 mg/day omeprazole) and one or two antibiotics (500 mg AMOX, 200 mg CLAR or 250 mg MNZ twice a day)
Number of subjects: 290
Study 1347332 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (158 patients, gastric ulcer, treated for 8 weeks)
Number of subjects: 607
Study 1347332 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (158 patients, gastric ulcer, treated for 8 weeks)
Number of subjects: 607
Study 1347332 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (148 patients, duodenal ulcer, treated for 6 weeks)
Number of subjects: 607
Study 1347332 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (143 patients, duodenal ulcer, treated for 6 weeks)
Number of subjects: 607
Study 1347332 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (gastric ulcer)
Number of subjects: 607
Study 1347332 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (gastric ulcer)
Number of subjects: 607
Study 1347332 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (duodenal ulcer)
Number of subjects: 607
Study 1347332 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (duodenal ulcer)
Number of subjects: 607
Study 2579716 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 cGy x 15 fractions
Number of subjects: 759
Study 2579716 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 cGy x 10 fractions
Number of subjects: 759
Study 2579716 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 cGy x 5 fractions
Number of subjects: 759
Study 2579716 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 cGy x 5 fractions
Number of subjects: 759
Study 2579716 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 cGy x 5 fractions
Number of subjects: 759
Study 30855089 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-field irradiation (LFI; tumor bed and elective lymph node region)
Number of subjects: 121
Study 30855089 — intervention group
Group type: COMPARATOR
Intervention: Small-field irradiation (SFI; tumor bed only)
Number of subjects: 121
Study 30855089 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-field irradiation (LFI)
Number of subjects: 121
Study 30855089 — intervention group
Group type: COMPARATOR
Intervention: Small-field irradiation (SFI)
Number of subjects: 121
Study 30855089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LFI and SFI
Number of subjects: 121
Study 28506664 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (70:30) via high flow nasal cannula at 8 L/min for 24 hours
Number of subjects: 48
Study 28506664 — intervention group
Group type: COMPARATOR
Intervention: Air–oxygen mixture 30% via high flow nasal cannula at 8 L/min for 24 hours
Number of subjects: 48
Study 26917493 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF)
Number of subjects: 40
Study 26917493 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap with porcine collagen matrix (CAF + CM)
Number of subjects: 40
Study 24885289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, response-based reading intervention over 3 years
Number of subjects: 0
Study 24885289 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual condition
Number of subjects: 0
Study 22278891 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable bladder scanner
Number of subjects: 145
Study 22278891 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (Control)
Number of subjects: 145
Study 20424499 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention (MPI)
Number of subjects: 361
Study 20424499 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention (MPI) in diabetic patients
Number of subjects: 361
Study 20424499 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 361
Study 18576906 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day in HIV-infected patients
Number of subjects: 32
Study 18576906 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg/day in HIV-negative patients (control)
Number of subjects: 32
Study 15860471 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT/VES
Number of subjects: 84
Study 15860471 — intervention group
Group type: COMPARATOR
Intervention: RCT/C
Number of subjects: 84
Study 12424548 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 68
Study 12424548 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg
Number of subjects: 68
Study 12424548 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg
Number of subjects: 68
Study 12424548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 10068105 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 165
Study 10068105 — intervention group
Group type: COMPARATOR
Intervention: Matched controls without shunts
Number of subjects: 165
Study 1709566 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 54
Study 1709566 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo tablet
Number of subjects: 54
Study 1709566 — intervention group
Group type: COMPARATOR
Intervention: No hypnotic
Number of subjects: 54
Study 6130752 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (up to 200 mg/day for 28 weeks)
Number of subjects: 45
Study 6130752 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure (3 hours total)
Number of subjects: 45
Study 6130752 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-aided relaxation (3 hours total)
Number of subjects: 45
Study 6130752 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-exposure homework
Number of subjects: 45
Study 6130752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 31764732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 61
Study 31764732 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (Control)
Number of subjects: 61
Study 30032288 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 106
Study 27027629 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed irradiation (1 second on, 1 second off) for 8 minutes
Number of subjects: 70
Study 27027629 — intervention group
Group type: COMPARATOR
Intervention: Continuous irradiation for 4 minutes
Number of subjects: 70
Study 25285540 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital, one-on-one, self-management education by a dedicated language-concordant registered nurse combined with telephone follow-up after discharge from a nurse practitioner.
Number of subjects: 700
Study 25285540 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700
Study 22287172 — intervention group
Group type: EXPERIMENTAL
Intervention: OsPr‐CMC (OPTIVE®)
Number of subjects: 82
Study 22287172 — intervention group
Group type: COMPARATOR
Intervention: Na‐HY (VISMED®)
Number of subjects: 82
Study 20114099 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral hamstring muscle stretching
Number of subjects: 120
Study 20114099 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral hamstring muscle stretching
Number of subjects: 120
Study 20114099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 17084887 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic curriculum intervention
Number of subjects: 7079
Study 17084887 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic with peer involvement intervention
Number of subjects: 7079
Study 17084887 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic with parent involvement intervention
Number of subjects: 7079
Study 17084887 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7079
Study 16892644 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 29
Study 16892644 — intervention group
Group type: COMPARATOR
Intervention: Control (no laser photocoagulation)
Number of subjects: 29
Study 15280979 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hyoscine
Number of subjects: 117
Study 15280979 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 117
Study 10735499 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine and interferon-alpha (DTIC/IFN)
Number of subjects: 100
Study 10735499 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine, BCNU, cisplatin and tamoxifen (DBCT)
Number of subjects: 100
Study 8679310 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation in HIV-infected patients
Number of subjects: 10
Study 8679310 — intervention group
Group type: COMPARATOR
Intervention: Olfactory stimulation in control subjects
Number of subjects: 10
Study 1558501 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine hydrochloride
Number of subjects: 50
Study 1558501 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline
Number of subjects: 50
Study 2864997 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation and 5-fluorouracil
Number of subjects: 157
Study 2864997 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation and Adriamycin (doxorubicin)
Number of subjects: 157
Study 31520730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) - 40,000 IU pancreatin, 3 times daily during meals for 3 months, n = 151
Number of subjects: 304
Study 31520730 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 153
Number of subjects: 304
Study 31520730 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT)
Number of subjects: 304
Study 31520730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 31236672 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical calcipotriol
Number of subjects: 60
Study 31236672 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB‐UVB)
Number of subjects: 60
Study 31236672 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (Topical calcipotriol + NB‐UVB)
Number of subjects: 60
Study 31236672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28642024 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (n = 38)
Number of subjects: 92
Study 28642024 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (n = 37)
Number of subjects: 92
Study 25721182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for anxiety
Number of subjects: 66